Suvretta Capital Management LLC Sells 208,118 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Suvretta Capital Management LLC lessened its stake in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 10.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,840,891 shares of the company's stock after selling 208,118 shares during the period. Suvretta Capital Management LLC owned about 3.68% of scPharmaceuticals worth $6,517,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SCPH. Legato Capital Management LLC bought a new position in scPharmaceuticals during the 4th quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of scPharmaceuticals during the fourth quarter worth $38,000. ProShare Advisors LLC bought a new position in scPharmaceuticals during the fourth quarter worth $48,000. Price T Rowe Associates Inc. MD bought a new position in scPharmaceuticals during the fourth quarter worth $54,000. Finally, Wells Fargo & Company MN lifted its holdings in scPharmaceuticals by 110.5% in the fourth quarter. Wells Fargo & Company MN now owns 18,407 shares of the company's stock valued at $65,000 after buying an additional 9,663 shares during the period. Institutional investors and hedge funds own 89.52% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Maxim Group decreased their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, March 20th.

scPharmaceuticals Trading Down 6.5%

Shares of NASDAQ:SCPH traded down $0.23 during mid-day trading on Tuesday, hitting $3.29. The company had a trading volume of 481,632 shares, compared to its average volume of 368,746. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. scPharmaceuticals Inc. has a one year low of $1.94 and a one year high of $5.65. The firm has a fifty day moving average price of $2.62 and a 200 day moving average price of $3.15. The company has a market capitalization of $173.69 million, a PE ratio of -1.73 and a beta of 0.17.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The company had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. As a group, research analysts forecast that scPharmaceuticals Inc. will post -1.53 EPS for the current year.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.